LEADER 04068nam 2200901z- 450 001 9910557118003321 005 20210501 035 $a(CKB)5400000000040866 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68343 035 $a(oapen)doab68343 035 $a(EXLCZ)995400000000040866 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aDiagnosis and Treatment of Small Bowel Disorders 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (146 p.) 311 08$a3-03943-873-5 311 08$a3-03943-874-3 330 $aOver the last few decades, remarkable progress has been made in understanding the aetiology and pathophysiology of diseases and many new theories emphasize the importance of the small bowel 'ecosystem' in the pathogenesis of acute and chronic illness. Emerging factors such as microbiome, stem cells, innate intestinal immunity and the enteric nervous system along with mucosal and endothelial barriers have key role in the development of gastrointestinal and extra-intestinal diseases. Therefore, the small intestine is considered key player in metabolic disease development, including diabetes mellitus, and other diet-related disorders such as celiac and non-celiac enteropathies. Another major field is drug metabolism and its interaction with microbiota. Moreover, the emergence of gut-brain, gut-liver and gut-blood barriers points toward the important role of small intestine in the pathogenesis of common disorders, such as liver disease, hypertension and neurodegenerative disease. However, the small bowel remains an organ that is difficult to fully access and assess and accurate diagnosis often poses a clinical challenge. Eventually, the therapeutic potential remains untapped. Therefore, it is due time to direct our interest towards the small intestine and unravel the interplay between small-bowel and other gastrointestinal (GI) and non-GI related maladies. 606 $aBiology, life sciences$2bicssc 606 $aResearch & information: general$2bicssc 610 $aadult stem cells 610 $aadverse events 610 $abiomarker 610 $abiomedical optical imaging 610 $acancer risk 610 $acapsule endoscopy 610 $aceliac disease 610 $aclinical diagnosis 610 $acollagenous colitis 610 $acolon cancer 610 $aCrohn's disease 610 $acystic fibrosis 610 $adysbiosis index 610 $aenteropathy 610 $afecal calprotectin 610 $afunctional gastrointestinal disorders 610 $agastroenterology 610 $agut brain axis 610 $agut microbiota 610 $ahyperspectral imaging 610 $ainflammatory bowel disease (IBD) 610 $aintestinal inflammation 610 $alung cancer 610 $amedical diagnostic imaging 610 $ameta-analysis 610 $amicrobiota 610 $amicroscopic colitis 610 $amucosal healing 610 $amultispectral imaging 610 $an/a 610 $aprebiotics 610 $aprobiotics 610 $aserology 610 $askin cancer 610 $asmall bowel 610 $asmall-bowel bulge 610 $asmall-bowel mass 610 $asquamous cell carcinoma 610 $asurgery 610 $asurgical site infections (SSIs) 610 $asynbiotics 610 $asystematic review 610 $avideo capsule endoscopy 615 7$aBiology, life sciences 615 7$aResearch & information: general 700 $aKoulaouzidis$b Anastasios$4edt$01307050 702 $aMarlicz$b Wojciech$4edt 702 $aKoulaouzidis$b Anastasios$4oth 702 $aMarlicz$b Wojciech$4oth 906 $aBOOK 912 $a9910557118003321 996 $aDiagnosis and Treatment of Small Bowel Disorders$93028656 997 $aUNINA